Endometrial ablation for refractory postmenopausal bleeding with continuous hormone replacement therapy
|
|
- Annice Norman
- 6 years ago
- Views:
Transcription
1 l FERTLTY AND STERLTY Vol. 62, 6, December 1994 Copyright e 1994 The American Fertility Society Printed on acid-free paper in U. S. A. Endometrial ablation for refractory postmenopausal bleeding with continuous hormone replacement therapy Lyman B. Spaulding, M.D., Ph.D.* Department of Obstetrics and Gynecology, St. Joseph Hospital, and Colorado Permanent Medical Group, Denver, Colorado Objective: To determine the role of endometrial ablation and benign uterine pathology in menopausal women with refractory bleeding who were treated with continuous hormone replacement therapy (HRT). Design: Prospective. Setting: Health maintenance organization. Patients: One hundred seventy-one menopausal women with an average age of 55 were enrolled in an algorithm of continuous HRT, endometrial biopsy for bleeding with initial therapy, doubling of the progestin dose, hysteroscopy, and endometrial resection-ablation for continued refractory bleeding. ntervention: Endometrial biopsy, hormone manipulation, office hysteroscopy, and hysteroscopic resection -ablation. Main Outcome Measures: Refractory menopausal bleeding and benign uterine pathology. Results: One hundred sixty-two women completed the study. One hundred six (65.4%) remained free of bleeding at the end of the initial 3 months of hormone therapy. Fifty-six (34.6%) had one or more bleeding episodes and required office biopsy and an increase in dosage of progestin. Bleeding ceased in an additional 35 (87%) while 21 (13%) continued to bleed. Those patients underwent endometrial resection-ablation. Surgical specimen demonstrated endometrial polyps, submucous leiomyomas, and adenomyosis in 85.7% of the cases. All patients are now free of bleeding. Conclusion: Many women become amenorrheic on the initial dose of continuous HRT; however, if bleeding continues, most stop when the dosage of progestin is doubled. Benign uterine pathology may cause refractory bleeding in a small group of patients but may be eliminated with endometrial resection-ablation. Fertil Steril1994;62: Key Words: Hormone replacement therapy, menopausal bleeding, endometrial ablation The beneficial effects of estrogen (E) replacement therapy in postmenopausal women are now accepted widely. Relief of vasomotor symptoms, decreased risk of cardiovascular disease, prevention of osteoporosis, and relief of genitourinary symptoms are recognized benefits (1). One of the major drawbacks fore replacement is the need for the addition of a progestin in those women with an intact uterus. Received January 28, 1994; revised and accepted July 22, * Reprint requests: Lyman B. Spaulding, M.D., Ph.D., Department of Obstetrics and Gynecology, Colorado Permanente Medical Group, 8383 West Alameda Avenue, Lakewood, Colorado (FAX: ). Troublesome bleeding may be the factor that causes many women to discontinue therapy. Continuous administration of an E and progestin potentially offers elimination of all bleeding. Although bleeding with continuous hormone replacement therapy (HRT) has been reported in 30% to 40% of patients within the first 4 months of use, it usually has decreased to approximately 12.5% after 9 months of therapy (2). This refractory bleeding may provoke patient anxiety, dissatisfaction, and decreased compliance (3). Resectoscopic therapy for abnormal bleeding has been used for approximately 20 years. Endometrial polyps and submucous myomas have been described in a high percentage of women undergoing Vol. 62, 6, December 1994 Spaulding Endometrial ablation and HRT 1181
2 surgical therapy for refractory bleeding (4). The current study was begun to investigate and treat refractory bleeding in patients treated with continuous HRT. The uterine pathology, as well as the effect of endometrial resection and ablation, in this clinical setting were evaluated. MATERALS AND METHODS One hundred seventy-one consecutive patients with an average age of 55 years (range, 43 to 72) presented with menopausal symptoms or dissatisfaction with their current hormone regimen from a large health maintenance organization serving the Denver metropolitan area between June 1991 and May 1993 and were seen by the author in a single clinic. The diagnosis of menopause was made if the patients presented with nocturnal vasomotor symptoms and failed to have withdrawal bleeding for 2 consecutive months after a progestational challenge (medroxyprogesterone acetate A], 10 mg for 10 days) or a serum FSH and LH 40 miu/ml (conversion factor to S unit, 1.00). This process identified 78 patients ( 45.6%) of the cohort. The remaining 93 patients (54.4%) had never been on HRT, with a number of years of no menses, or had been tried on cyclic replacement and were desirous of no more monthly withdrawal bleeding. The average age of the study population was 55 years (range 43 to 72 years), gravidity 2.7 (range 0 to 8), parity 2.35 (range 0 to 6), and weight 67.9 kg (range 42.3 to kg). The ethnic breakdown was Anglo, 160 (93.5%); Hispanic, 9 (5.3%); and Asian, 2 (1.2%). All patients were begun on daily conjugated equine E (Premarin; Ayerst Laboratories, nc., Philadelphia, PA) mg and MPA (Provera; The Upjohn Company, Kalamazoo, M) 2.5 mg. Those with no bleeding after the first 3 months of therapy were requested to return in another 6 months, whereas those with bleeding underwent an endometrial biopsy and the dose of MPA was increased to 5.0 mg/d. After biopsy, patients were seen again in 3 months. Patients without bleeding were scheduled to be seen in another 6 months. Those who continued to bleed underwent office hysteroscopy (Olympus HYF Type P, Lake Success, NY) and were counseled individually and provided with written material outlining their options: stopping all hormone therapy, endometrial resection-ablation, or hysterectomy. All patients requested resection-ablation (Fig. 1). An outpatient ambulatory surgical center was used for all ablations. Anesthesia was induced using the general endotracheal technique. nitially, the patient's bladder was emptied by catheter and the cervical stroma infiltrated with 2 ml of a dilute vasopressin solution (20 U of vasopressin in 30 ml of saline) at the 2, 4, 8, and 10 o'clock position. The internal cervical os was dilated to 9 Hegar, and the continuous flow 22FR resectoscope (Olympus Hystero-resectoscope, Malpitas, CA) was used for all procedures. Chilled sorbitol solution (3.3%) with the CDS rrigation System (Zimmer Patient Care Division, Dover, OH) was used to distend the uterine cavity with intrauterine pressure no greater than 78 mm Hg. No endometrial preparation was used, and HRT was continued before and immediately after the surgical procedure. The ablation technique was accomplished in two steps. First, endometrial polyps, submucous myomas, and endometrial strips, from the entire cavity to a depth of 3 to 4 mm were resected using the loop electrode at loow of cutting current. These tissue samples were removed from the endometrial cavity using the Synevac Vacuum Curettage (Berkeley Medevices, nc., Berkeley, CA). Second, the entire uterine cavity was coagulated using the rollerbarrel electrode at loow of coagulation current. The electrical generator used was the Force 2 (Valley Lab, n., Boulder, CO). All tissue specimens were submitted to pathology. Patients were observed in the outpatient facility and discharged to home within 3 hours. All patients in this study were followed for at least 9 months, and the longest follow-up was 32 months. RESULTS One hundred seventy-one menopausal patients were entered into the study. Nine patients did not complete the study. Four women stopped hormone therapy because of unacceptable bleeding. One stopped because of a newly diagnosed breast cancer, 1 because of emotional problems, 1 lost her health insurance, and 2 patients were lost to follow-up. At the end of the initial 3 month phase 106 (65.4%) women reported no bleeding and experienced no further bleeding during the study. Fifty-six women (34.6%) reported bleeding and underwent office endometrial biopsy. The dosage of progestational agent (MP A) was then increased to 5 mg. All biopsies were benign (Table 1). The single patient with insufficient tissue underwent a second office biopsy plus ultrasound imaging of the endometrial stripe. The second biopsy was reported also as insufficient tissue and the endometrial strip was 3 mm in 1182 Spaulding Endometrial ablation and HRT Fertility and Sterility
3 Diagnosis of menopause (n = 171) Continuous hormone replacement therapy* Discontinued patients (n = 9) Three months (n = 162) Bleeding (n =56) Office biopsy (nonmalignant) + Progestational agentt Three months No bleeding (n = 106) Followup at six months Figure 1 Management protocol for continuous HRT. Bleeding (n = 21) Office hysteroscopy Endometrial ablation No bleeding (n = 35) Followup at six months thickness. These 56 patients were seen again after a second 3-month interval. After increasing MPA to 5.0 mg, 35 additional patients became amenorrheic (87%) but 21 (12.9%) continued to bleed. Endometrial histology from these 21 women were similar to those previously sampled. (Table 2). Endometrial polyps, submucous leiomyomas, and normal cavities were observed in this subset of patients at office hysteroscopy. One patient was noted to have polyps and leiomyomas. All patients with refractory bleeding underwent endometrial resection-ablation with the exception of 1 patient. Because of equipment malfunction, this patient only had resection performed. The pathological specimens were benign with endometrial polyps (47.6%) and submucous Table 1 Endometrial Histology After the First 3 Months of Treatment* Diagnosis nactive endometrium Atrophic nsufficient tissue * n = (76.8)t 6 (10.7) 6 (10.7) 1 (1.8) leiomyomata (33.3%) predominating (Table 3). A number of specimens contained more than a single pathological entity. Sorbitol (3.3%) uptake averaged 337 ml (range, 0 to 1,300 ml). Blood loss was minimal, and there were no complications in this series. None of these patients are bleeding at this time. DSCUSSON Approximately 36 million American women could spend one third of their lives in a hypoestrogenic state. With modern HRT, this condition can be avoided. Estrogen replacement can be accomplished by pills, patches, subdermal capsules and M injections. However, endometrial hyperplasia and uterine cancer have been associated with prolonged use of unopposed E (5). By decreasing nuclear E receptors (6), blocking DNA synthesis (7), and decreasing cell multiplication (8), progestins offer a protective effect when combined with E. Replacement therapy has been prescribed to mimic the natural monthly withdrawal cycle, but after 40 years of monthly menses, most menopausal women would like to eliminate these bleeding episodes. Daily ingestion of an E and a progestin (con- Vol. 62, 6, December 1994 Spaulding Endometrial ablation and HRT 1183
4 Table 2 Patient Characteristics With Refractory Bleeding* Endometrial histology Office hysteroscopy nactive endometrium Atrophic endometrium nsufficient tissue 16 (76.2)t Endometrial polyps Submucous leiomyoma Normal cavity 12 (54.5)t 7 (31.8) 3 (13.6) * n = 21. tinuous HRT) has the potential to eliminate all bleeding. Although 90% of women on cyclic HRT experience withdrawal bleeding (9), only 30% to 40% have bleeding on daily therapy. This incidence of bleeding has decreased to 12.5% by 9 months (2) and approximately 10% by 1 year. Perimenopausal status (10), dosage of E (11), patient weight (12), progestational dose (13), and progestational type (14) have all been reported to influence bleeding with daily combined therapy. Any bleeding while on replacement therapy limits compliance. n one study 57% of women stopped taking cyclic therapy because of withdrawal bleeding. n hysterectomized women, only 21% discontinued E therapy (15). Bleeding appears to be the number one reason for discontinuing HRT. Because of this common problem, a protocol of biopsy, hormone manipulation, office hysteroscopy, and endometrial ablation was initiated (Fig. 1). Medroxyprogesterone acetate was increased to 5.0 mg/d after 3 months of irregular bleeding. Although Weinstein et al.(16) noted no difference in bleeding patterns between 2.5 and 5.0 mg, many women in our patient population stopped bleeding on the 5.0-mg dose, yielding an 87% level of amenorrhea at 6 months of therapy. Weinstein et al. (16) also demonstrated that the higher dose of MP A did not cause deterioration of lipid profile. No hyperplasia or overt cancers were noted on office biopsy Table 3 Histologic Features at Endometrial Resection-Ablation* Diagnosis Endometrial polyps Leiomyomata nactive endometrium Adenomyosis Cystic atrophy * n = (47.6) 7 (33.3) 3 (14.3) or surgical specimens. This finding is consistent with other reports (17) and is thought to be due to the antiestrogen effect of the progestins. Recent reports that have included a few postmenopausal women, describing abnormal bleeding due to benign uterine pathology are consistent with this study. n Loffer's (4) report on large symptomatic intrauterine growths, he included 6 postmenopausal women who were noted to have polyps ( 4/ 16) and leiomyoma (2/16) as the cause of their bleeding. Brooks and Serdan (18) included 13 postmenopausal women in their report of 26 women bleeding after the age of 50. Overall, 58% of their patients demonstrated adenomyosis, whereas only 35% and 4% were found to have leiomyoma and polyps, respectively. The series by tzkowic (19) contained 5 postmenopausal patients in his report of 37 women with bleeding because of submucous leiomyomas. These women accounted for 13.5% of his population. Similarly, lndman (20) described 7 postmenopausal women in his 51 patients treated for menorrhagia for a similar rate of 13.7%. The results in this portion ofthe study of 21 menopausal women more closely match Loffer's work with our finding of adenomyosis in only one patient. Although benign uterine pathology causing clinical problems is diminished in frequency at the menopause, there appears to be a small group of patients who when challenged by HRT respond with unacceptable uterine bleeding. Whether this bleeding is due to hormonal stimulation of polyps and submucous leiomyomas that were present before HRT or the induction of new growths remains to be determined. Even though this study was not randomized and lacked a control group, the protocol described may select for those postmenopausal patients who can best benefit from removal of benign uterine pathology. Conclusions to be drawn from this study include the following: [l]many women will cease or continue to have no menses on the initial dose of continuous hormone therapy (65.4%); [2]increasing 1184 Spaulding Endometrial ablation and HRT Fertility and Sterility
5 - the dose of progestin may enhance levels of amenorrhea (87%); [3]benign uterine pathology may cause refractory bleeding in a small group of patients (13%); and [4]endometrial resection-ablation may correct the bleeding, thus encouraging them to maintain compliance with HRT. REFERENCES 1. American College of Obstetricians and Gynecologists, Hormone replacement therapy. ACOG Technical Bulletin no Washington, DC: American College of Obstetricians and Gynecologists, Prough SG, Aksel S, Wiebe H, Shepherd, J. Continuous estrogen/progestin therapy in menopause. Am J Obstet Gynecol 1987;157: Derman SG, Rehnstrom J, Neuwirth, RS. The long-term effectiveness of hysteroscopic treatment of menorrhagia and leiomyomas. Obstet Gynecol1991;77: Loffer FD. Removal of large symptomatic intrauterine growth by the hysteroscopic resectoscope. Obstet Gynecol 1990;76: World Health Organization. Research on the menopause. World Health Organization Technical Report Series 670. Geneva: WHO, Hsveh AJW, Peck EJ, Clark JH. Control of uterine estrogen receptor levels by progesterone. Endocrinology 1976;98: Whitehead Ml, Townsend PT, Pryse-Davies J, Ryder JA, King RJB. Effects of estrogens and progestins on the biochemistry and morphology of the postmenopausal endometrium. N Eng! J Med 1981;305: Gerschenson LE, Berliner J, Yang JJ. Diethylstilbestrol and progesterone regulation of cultured rabbit endometrial cell growth. Cancer Res 1974;34: Whitehead Ml, Hillard TC, Crook D. The role and use of progestogens. Obstet Gynecol 1990;75:59S-76S. 10. Mattson L, Samsioe G. Estrogen-progestogen replacement in climacteric women, particularly as regards a new type of continuous regimen. Acta Obstet Gynecol Scand Suppl 1985;130: Magos AL, Brincat M, Studd JWW, WardLE, Schlesinger P, O'Dowd T. Amenorrhea and endometrial atrophy with continuous oral estrogen and progestogen therapy on postmenopausal women. Obstet Gynecol 1985;65: Sporrong T, Samsioe G, Larsen S, Mattson LA. A novel statistical approach to analysis of bleeding patterns during continuous hormone replacement therapy. Maturitas 1989;11: Yancey MK, Hannan CJ Jr, Plymate SR, Stone K, Friedl KE, Wright JR. Serum lipids and lipoproteins in continuous or cyclic medroxyprogesterone acetate treatment in postmenopausal women treated with conjugated estrogens. Fertil Steril 1990;54: Jensen J, Riis BJ, Strom V, Christiansen C. Continuous estrogen-progestogen treatment and serum lipoproteins in postmenopausal women. Br J Obstet Gynaecol 1987;94: Hemminki F, Brambilla DJ, MacKinlay SM, Posner JG. Use of estrogens among middle-aged massachusetts women. DCP 1991;25: Weinstein L, Bewtra C, Gallagher JC. Evaluation of a continuous combined low dose regimen of estrogen progestin for treatment of the menopausal patient. Am J Obstet Gynecol 1990;162: Bewtra C, Kable WT, Gallagher JC. Endometrial histology and bleeding patterns in menopausal women treated with estrogen and continuous or cyclic progestin. J Reprod Med 1988;33: Brooks PG, Serden SP. Endometrial ablation in women with abnormal uterine bleeding aged fifty and over. J Reprod Med 1992;37: tzkowic D. Submucous fibroids: clinical profile and hysteroscopic management. Aust NZ J Obstet Gynecol 1993; 33: ndman PD. Hysteroscopic treatment of menorrhagia associated with uterine leiomyomas. Obstet Gynecol 1993;81: Vol. 62, 6, December 1994 Spaulding Endometrial ablation and HRT 1185
Frequency of menses. Duration of menses 3 days to 7 days. Flow/amount of menses Average blood loss with menstruation is 60-80cc.
Frequency of menses 24 days (0.5%) to 35 days (0.9%) Age 25, 40% are between 25 and 28 days Age 25-35, 60% are between 25 and 28 days Teens and women over 40 s cycles may be longer apart Duration of menses
More informationPrevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: influence of bleeding pattern and secretory changes*
FERTILITY AND STERILITY Vol. 59, No.5, May 1993 Copyright e 1993 The American Fertility Society Printed on acid-free paper in U.S.A. Prevention of endometrial hyperplasia by progesterone during long-term
More informationHysteroscopic Endometrial Destruction, Optimum Method for Preoperative Endometrial Preparation: A Prospective, Randomized, Multicenter Evaluation
SCIENTIFIC PAPER Hysteroscopic Endometrial Destruction, Optimum Method for Preoperative Endometrial Preparation: A Prospective, Randomized, Multicenter Evaluation O. Shawki, MD, A. Peters, DO, S. Abraham-Hebert,
More informationEndometrial Cancer Biopsy of the endometrium Evaluation of women of all ages
Endometrial Cancer Biopsy of the endometrium Evaluation of women of all ages Barbara S. Apgar, MD, MS Professor of Family Medicine University of Michigan Health System Ann Arbor, Michigan Cancer of the
More information5/5/2010 FINANCIAL DISCLOSURE. Abnormal Uterine Bleeding. Is This A Problem? About me % of visits to gynecologist
Abnormal Uterine FINANCIAL DISCLOSURE I HAVE NO FINANCIAL INTEREST IN ANY OF THE PRODUCTS MENTIONED IN MY PRESENTATION Bryan K. Rone, M.D. University of Kentucky Obstetrics and Gynecology May 5, 2010 About
More informationRole of diagnostic hysteroscopy in evaluation of abnormal uterine bleeding and its histopathological correlation
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Chaudhari KR et al. Int J Reprod Contracept Obstet Gynecol. 2014 Sep;3(3):666-670 www.ijrcog.org pissn 2320-1770 eissn 2320-1789
More informationMenopausal Symptoms. Hormone Therapy Products Available in Canada for the Treatment of. Physician Desk Reference - 3rd Edition
Hormone Therapy Products Available in Canada for the Treatment of Menopausal Symptoms Physician Desk Reference - 3rd Edition A clinical resource provided to you by: The Society of Obstetricians and Gynaecologists
More informationInvestigation of abnormal uterine bleeding in perimenopausal women by hysteroscopy and endometrial biopsy
Gynecol Surg (2005) 2: 51 55 DOI 10.1007/s10397-004-0076-2 CURRENT REFERENCES I. Stamatellos Æ P. Stamatopoulos Æ D. Rousso E. Asimakopoulos Æ C. Stamatopoulos Æ I. Bontis Investigation of abnormal uterine
More informationHysterectomy : A Clinicopathologic Correlation
Bahrain Medical Bulletin, Vol. 28, No.2, June 2006 Hysterectomy : A Clinicopathologic Correlation Layla S Abdullah, FRCPC* Objective : To study the most common pathologies identified in hysterectomy specimens
More informationConflicts 10/5/2016. Abnormal Uterine Bleeding. Objectives Review diagnosis and updated nomenclature. Management options for acute and chronic AUB.
Abnormal Uterine Bleeding Barbara L. Keller, MD JD Naval Hospital Oak Harbor OB/GYN Physician Conflicts I have no conflicts or financial interests to disclose. Objectives Review diagnosis and updated nomenclature.
More informationAUB. Postmenopausal. Approximately 1 of every 8 postmenopausal. Rule out endometrial cancer first OBG COVER ARTICLE
OBG MANAGEMENT COVER ARTICLE Postmenopausal AUB Rule out endometrial cancer first When a postmenopausal woman presents with abnormal uterine bleeding, endometrial cancer is the biggest concern. But a host
More informationbleeding Studies naar de diagnostiek van endom triumcarcinoom bij vrouwen met postm nopauzaal bloedverlies. Studies on the
Studies on the diagnosis of endometria cancer in women with postmenopausal bleeding. Studies naar de diagnostiek va endometriumcarcinoom bij vrouwen m postmenopauzaal bloedverlies. Studies on the diagnosis
More informationHysteroscopic polypectomy in 240 premenopausal and postmenopausal women
Hysteroscopic polypectomy in 240 premenopausal and postmenopausal women Sangchai Preutthipan, M.D., and Yongyoth Herabutya, F.R.C.O.G. Department of Obstetrics and Gynaecology, Faculty of Medicine, Ramathibodi
More informationPERIMENOPAUSE. Objectives. Disclosure. The Perimenopause Perimenopause Menopause. Definitions of Menopausal Transition: STRAW.
PERIMENOPAUSE Patricia J. Sulak, MD Founder, Living WELL Aware LLC Author, Should I Fire My Doctor? Author, Living WELL Aware: Eleven Essential Elements to Health and Happiness Endowed Professor Texas
More informationLearning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories
Learning Objectives Identify common symptoms of the menopause transition Understand the risks and benefits of hormone replacement therapy (HRT) Be able to choose an appropriate hormone replacement regimen
More informationExcessive menstrual blood loss
Ian Chilcott Excessive menstrual blood loss >80mls - That interferes with physical, emotional, social and material quality of life 1 in 20 women aged 30 to 49 years consult their GP each year with menorrhagia
More informationSubject Index. Cavaterm, endometrial ablation complications 146, 150 contraindications 152 cost analysis compared with hysterectomy
OOOOOOOOOOOOOOOOOOOOOOOOOOOOOO Subject Index Abnormal uterine bleeding, see also Adenomyosis, Endometrial cancer, Menorrhagia dilatation and curettage 21, 22, 25 hysteroscopy of premenopausal women anesthesia
More informationPALM-COEIN: Your AUB Counseling Guide
PALM-COEIN: Your AUB Counseling Guide 10 million+ Treat the cause, not the symptom In the U.S, more than 10 million women between the ages of 35 and 49 are affected by AUB 1 Diagnosis Cause Structural
More informationNon-contraceptive Uses of the Levonorgestrel Intrauterine Device Elena Gates, MD http://www.mirena-us.com/pvs1/pri/whatisframe.html Progestin levels with LNG- IUS Lower plasma levels Mirena 150-200 pg/ml
More informationMenstrual Disorders & Ambulatory Gynaecology
Menstrual Disorders & Ambulatory Gynaecology Mr. Nagui Lewis Aziz M B, CH B, FRCOG Consultant Gynaecologist The Royal Oldham Hospital 01/09/2018 Heavy menstrual bleeding (HMB ) is a common problem responsible
More informationDIAGNOSTIC HYSTEROSCOPY IN ABNORMAL UTERINE BLEEDING & IT'S HISTOPATHOLOGIC CORRELATION: OUR EXPERIENCE
Original Article DIAGNOSTIC HYSTEROSCOPY IN ABNORMAL UTERINE BLEEDING & IT'S HISTOPATHOLOGIC CORRELATION: OUR EXPERIENCE Abstract : 1 2 3 4 Neetha Nandan, Lakshmi Manjeera, Supriya Rai & Mangala Gowri
More information5. Summary of Data Reported and Evaluation
326 5. Summary of Data Reported and Evaluation 5.1 Exposure data Combined estrogen progestogen menopausal therapy involves the co-administration of an estrogen and a progestogen to peri- or postmenopausal
More informationTransvaginal ultrasonography and hysteroscopy in postmenopausal bleeding a prospective study
Acta Obstet Gynecol Scand 2001; 80: 856 862 Copyright C Acta Obstet Gynecol Scand 2001 Printed in Denmark All rights reserved Acta Obstetricia et Gynecologica Scandinavica ISSN 0001-6349 ORIGINAL ARTICLE
More informationSaid Saleh. Department of Obstetrics and Gynecology, Faculty of Medicine, Menoufia University, Menoufia, Egypt
ARC Journal of Gynecology and Obstetrics Volume 1, Issue 2, 2016, PP 7-12 ISSN No. (Online) 2456-0561 http://dx.doi.org/10.20431/2456-0561.0102003 www.arcjournals.org Efficacy and Acceptability of two
More informationDepartment of Obstetrics and Gynecology, Osaka Medical College, Takatsuki-city, Osaka , Japan. Pituitary gonadotropin, Clinical managament
Original Article Adequate Reduction Degree of Pituitary Gonadotropin Level in the Clinical Management of Short-Term Hormone Replacement Therapy of Women with Menopausal Symptoms Department of Obstetrics
More informationOver the past year, a few gems have been
UPDATE Abnormal uterine bleeding Howard T. Sharp, MD Dr. Sharp is Professor and Vice Chair for Clinical and Quality Activities, Department of Obstetrics and Gynecology, University of Utah Health Sciences
More informationIntrauterine and subdermal progestin administration postmenopausal hormone replacement therapy
FERTILITY AND STERILITY Vol. 63, No.2, February 1995 Copyright c 1995 American Society for Reproductive Medicine Printed on acid-free paper in U. S. A. Intrauterine and subdermal progestin administration
More informationThe 6 th Scientific Meeting of the Asia Pacific Menopause Federation
Abnormal uterine bleeding in the perimenopause Perimenopausal menstrual problems are among the most common causes for family practitioner and specialist referral. Often it is due to the hormone changes
More informationof AUB DISCLOSURES 10/29/2018
of AUB DR. DEBRA GIERUT MD DEPARTMENT OF OBSTETRICS AND GYNECOLOGY KAISER PERMANENTE, ORANGE COUNTY DISCLOSURES I have no financial disclosures Lisa Samerdyke, the Director of National Accounts for Hologic
More informationAbnormal uterine bleeding:
Primary Care Women s Health Forum 16th June 2010 Abnormal uterine bleeding: The University Of Birmingham T Justin Clark MD (Hons), MRCOG Consultant Obstetrician and Gynaecologist Birmingham Women s Hospital
More informationGynecologic Decision Making Based on Sonographic Findings
Gynecologic Decision Making Based on Sonographic Findings Mindy Goldman, MD Department of Obstetrics & Gynecology & Vickie A. Feldstein, MD Department of Radiology University of California, San Francisco
More information5 Mousa Al-Abbadi. Ola Al-juneidi & Obada Zalat. Ahmad Al-Tarefe
5 Mousa Al-Abbadi Ola Al-juneidi & Obada Zalat Ahmad Al-Tarefe Abnormal Uterine Bleeding (AUB) AUB is a very common scenario or symptom where women complain of menorrhagia (heavy and/or for long periods),
More informationManagement of Abnormal Uterine Bleeding. Julie Strickland MD, MPH University of Missouri Kansas City Department of Obstetrics and Gynecology
Management of Abnormal Uterine Bleeding Julie Strickland MD, MPH University of Missouri Kansas City Department of Obstetrics and Gynecology AUB Abnormal uterine bleeding (AUB): fairly broad term referring
More informationManaging Menstrual Disorders
Managing Menstrual Disorders David G. Weismiller, MD, ScM, FAAFP Professor Department of Family Medicine The Brody School of Medicine at East Carolina University Greenville, North Carolina Learning Objectives
More informationComparison of Office Hysteroscopy, Transvaginal Ultrasonography and Endometrial Biopsy in Evaluation of Abnormal Uterine Bleeding
JSLS Comparison of Office Hysteroscopy, Transvaginal Ultrasonography and Endometrial Biopsy in Evaluation of Uterine Bleeding Lubna Pal, MD, L. Lapensee, MD, T.L. Toth, MD, K.B. Isaacson, MD ABSTRACT INTRODUCTION
More informationENDOMETRIAL RESECTION FOR THE TREATMENT OF MENORRHAGIA ENDOMETRIAL RESECTION FOR THE TREATMENT OF MENORRHAGIA. Study Patients
ENDOMETRIAL RESECTION FOR THE TREATMENT OF MENORRHAGIA ENDOMETRIAL RESECTION FOR THE TREATMENT OF MENORRHAGIA HUGH O CONNOR, M.R.C.O.G., AND ADAM MAGOS, M.D. ABSTRACT Background Endometrial resection is
More informationHysteroscopy - current trends and challenges
J Obstet Gynecol India Vol. 58, No. 1 : January/February 2008 pg 57-62 Original Article Hysteroscopy - current trends and challenges Gour A, Zawiejska A, Mettler L Department of Obstetrics and Gynaecology,
More informationEffects of TX-001HR on Uterine Bleeding Rates in Menopausal Women with Vasomotor Symptoms
Effects of TX-001HR on Uterine Bleeding Rates in Menopausal Women with Vasomotor Symptoms Photo (compulsory) Steven R Goldstein, MD 1 ; Ginger D Constantine, MD 2 ; David F Archer, MD 3 ; James H Pickar,
More informationA cost-utility analysis of low-dose hormone replacement therapy in postmenopausal women with an intact uterus Swift J A, Conway P, Purdie D W
A cost-utility analysis of low-dose hormone replacement therapy in postmenopausal women with an intact uterus Swift J A, Conway P, Purdie D W Record Status This is a critical abstract of an economic evaluation
More informationGayatrri Anipindi *, Vani I. Original Research Article. Abstract
Original Research Article Role of levonorgestrel releasing intrauterine device in management of heavy menstrual bleeding: A safe and effective option for all PALM COEIN variants Gayatrri Anipindi *, Vani
More informationOut Patient Hysteroscopy Unit GUIDELINES
Out Patient Hysteroscopy Unit GUIDELINES 1 AIMS The aim of the menstrual assessment clinic [MAC] (incorporating outpatient hysteroscopy) at Queen Charlotte s and Chelsea Hospital will be to provide a one-stop
More informationREPRODUCTIVE ENDOCRINOLOGY
REPRODUCTIVE ENDOCRINOLOGY FERTILITY AND STERILITY VOL. 76, NO. 2, AUGUST 2001 Copyright 2001 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in
More informationSTOP/START. On the Web. 12 intraoperative videos from Dr. Garcia, at
Diagnostic hysteroscopy spies polyp previously missed on transvaginal ultrasound and dilation and curettage. STOP performing dilation and curettage for the evaluation of abnormal uterine bleeding START
More informationDysfunctional Uterine Bleeding
Long term effects of PCOS Dysfunctional Uterine Bleeding Dr. Arulmozhi Ramarajan Church of South India Hospital, Bangalore Abnormal uterine bleeding Affects health-related QOL Causes social embarrasment
More informationCorrelation of Endometrial Thickness with the Histopathological Pattern of Endometrium in Postmenopausal Bleeding
DOI 10.1007/s13224-014-0627-z ORIGINAL ARTICLE Correlation of Endometrial Thickness with the Histopathological Pattern of Endometrium in Postmenopausal Bleeding Singh Pushpa Dwivedi Pooja Mendiratta Shweta
More informationPerimenopausal Age Group (45-55yrs): For Early Detection And Treatment.
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 17, Issue 9 Ver. 4 (September. 2018), PP 73-77 www.iosrjournals.org Perimenopausal Age Group (45-55yrs):
More informationENDOMETRIAL ABLATION: TRENDS AND CHALLENGES IN 2017
ENDOMETRIAL ABLATION: TRENDS AND CHALLENGES IN 2017 Philippe Laberge MD FRCSC ACGE Professor Obstetrics and Gynecology Laval University Quebec, Canada Disclosures I have used products or done clinical
More informationMedical Management of Fibroids Esmya. Dr Paula Briggs Consultant in Sexual and Reproductive Health
Medical Management of Fibroids Esmya Dr Paula Briggs Consultant in Sexual and Reproductive Health Treatment options for Uterine Fibroids ESMYA Selective Uterine Artery Embolisation Fibroid ablation (hysteroscopic
More informationLong-term Results in the Treatment of Menorrhagia and Hypermenorrhea With a Thermal Balloon Endometrial Ablation Technique
Longterm Results in the Treatment of Menorrhagia and Hypermenorrhea With a Thermal Balloon Endometrial Ablation Technique L. Mettler, Prof Dr Med SCIENTIFIC PAPER ABSTRACT Background and Objectives: Evaluation
More informationEndometrial line thickness in different conditions.
Endometrial line thickness in different conditions 1 Endometrial thickens in response to Rising estrogen levels during the menstrual cycle and then shedding endometrial at the times of menses 2 The thickens
More informationSummary CHAPTER 1. Introduction
Summary This thesis aims to evaluate the diagnostic work-up in postmenopausal women presenting with abnormal vaginal bleeding. The Society of Dutch Obstetrics and Gynaecology composed a guideline, which
More informationJSLS. Combining Myoma Coagulation with Endometrial Ablation/Resection Reduces Subsequent Surgery Rates. Herbert A. Goldfarb, MD ABSTRACT INTRODUCTION
JSLS Combining Myoma Coagulation with Endometrial Ablation/Resection Reduces Subsequent Surgery Rates Herbert A. Goldfarb, MD ABSTRACT Background: This study compares results of endometrial ablation alone
More informationClassification of Benign Endometrial Glandular Cells in Cervical Smears from Postmenopausal Women
60 CANCER CYTOPATHOLOGY Classification of Benign Endometrial Glandular Cells in Cervical Smears from Postmenopausal Women Edi Brogi, M.D., Ph.D. Rosemary Tambouret, M.D. Debra A. Bell, M.D. Department
More informationComparison of Sonography, Sonohysterography, and Hysteroscopy for Evaluation of Abnormal Uterine Bleeding
Comparison of Sonography, Sonohysterography, and Hysteroscopy for Evaluation of Abnormal Uterine Bleeding Mo H. Saidi, MD, R. Kent Sadler, MD, Vernon D. Theis, MD, Bruce D. Akright, MD, Scott A. Farhart,
More informationAppendix: Reference Table of HT Brand Names
Appendix: Reference Table of HT Brand Names This is a full reference table in alphabetical order, of Brand Name drugs used in HT. It is the basis for prescription advice throughout this handbook. Drug
More informationHYSTEROSCOPIC SURGERY AT THE AGA KHAN HOSPITAL, NAIROBI. R.B. PARKAR and N. G. THAGANA ABSTRACT
336 EAST AFRICAN MEDICAL JOURNAL July 2004 East African Medical Journal Vol. 81 No. 7 July 2004 HYSTEROSCOPIC SURGERY AT THE AGA KHAN HOSPITAL, NAIROBI R. B., Parkar, MBBS, MMed, Consultant Obstetrician,
More informationAulia Rahman, S. Ked Endang Sri Wahyuni, S. Ked Nova Faradilla, S. Ked
Authors : Aulia Rahman, S. Ked Endang Sri Wahyuni, S. Ked Nova Faradilla, S. Ked Faculty of Medicine University of Riau Pekanbaru, Riau 2009 Files of DrsMed FK UR (http://www.files-of-drsmed.tk 0 INTTRODUCTION
More informationElaina Sexton, MD, MSc Obstetrics and Gynecology St. Vincent s Hospital. Objectives
Elaina Sexton, MD, MSc Obstetrics and Gynecology St. Vincent s Hospital Objectives Definition of normal menstrual cycle and abnormal uterine bleeding (AUB) Evaluation of AUB Medical options for AUB Surgical
More informationGLOBAL ENDOMETRIAL ABLATION TECHNOLOGY
GLOBAL ENDOMETRIAL ABLATION TECHNOLOGY Training: Part 1 Anatomy and Physiology Female Anatomy Normal Uterus Female Anatomy Normal Uterus Female Anatomy Uterine Positions Abnormal Uterus Retroflexed Normal
More informationAbnormal Uterine Bleeding. Richard Dover Specialist gynaecologist
Abnormal Uterine Bleeding Richard Dover Specialist gynaecologist A pragmatic guide. Wide topic range What s not coming up Precocious puberty Menorrhagia well maybe just a little Topics Adolescents IMB
More informationMANAGEMENT OF REFRACTORY ENDOMETRIOSIS
(339) MANAGEMENT OF REFRACTORY ENDOMETRIOSIS Serdar Bulun, MD JJ Sciarra Professor and Chair Department of Ob/Gyn Northwestern University ENDOMETRIOSIS OCs Teenager: severe dysmenorrhea often starting
More informationManagement of Endometrial Hyperplasia
Management of Endometrial Hyperplasia I have nothing to disclose. Stefanie M. Ueda, M.D. Assistant Clinical Professor UCSF Division of Gynecologic Oncology Female Malignancies in the United States New
More informationASHERMAN S SYNDROME FOLLOWING THERMAL ABLATION OF THE ENDOMETRIUM Sheila K. Pillai 1, Bhuvana S 2, Jaya Vijayaraghavan 3
ASHERMAN S SYNDROME FOLLOWING THERMAL ABLATION OF THE ENDOMETRIUM Sheila K. Pillai 1, Bhuvana S 2, Jaya Vijayaraghavan 3 HOW TO CITE THIS ARTICLE: Sheila K. Pillai, Bhuvana S, Jaya Vijayaraghavan. Asherman
More informationINTRODUCTION. British Journal of Obstetrics and Gynaecology March 2000, Vol107, pp
British Journal of Obstetrics and Gynaecology March 2000, Vol107, pp. 329-334 The effect of submucous fibroids on the dose-dependent modulation of uterine bleeding by trimegestone in postmenopausal women
More informationDepot leuprolide acetate with estrogen and progestin add-back for long-term treatment of premenstrual syndrome*t
FERTILITY AND STERILITY Vol. 62, No. 5, November 1994 Copyright 1994 The American Fertility Society Printed on acid-free paper in U. S. A. Depot leuprolide acetate with estrogen and progestin add-back
More informationCASE 4- Toy et al. CASE FILES: Obstetrics & Gynecology
CASE 4- Toy et al. CASE FILES: Obstetrics & Gynecology A 49-year-old woman complains of irregular menses over the past 6 months, feelings of inadequacy, vaginal dryness, difficulty sleeping, and episodes
More informationPRM Associated Endometrial Change Introduction & Illustrations 12-Feb-2012
Introductory Remarks: These images are from clinical trial endometrial samples collected by catheter biopsy. They are presented with a low power section view with selected higher power images to show detailed
More informationHysteroscopy in women with abnormal uterine bleeding on hormone replacement therapy: a comparison with postmenopausal bleeding
FERTILITY AND STERILITY Copyright 1996 American Society for Reproductive Medicine Vol. 65, No, 6, June 1996 Printed on acid-free paper in U. S. A Hysteroscopy in women with abnormal uterine bleeding on
More informationInternational Journal of Medical and Health Sciences
International Journal of Medical and Health Sciences Journal Home Page: http://www.ijmhrs.net ISSN:2277-4505 Original article Comparison Of Imaging Modalities In Abnormal Uterine Bleeding : Correlation
More informationOrals,Transdermals, and Other Estrogens in the Perimenopause
Orals,Transdermals, and Other Estrogens in the Perimenopause Cases Denise Black, MD, FRCSC Assistant Professor, Obstetrics, Gynecology and Reproductive Sciences University of Manitoba 6/4/18 197 Faculty/Presenter
More informationCOLLEGE OF OBSTETRICIANS AND GYNAECOLOGISTS, SINGAPORE 2006
COLLEGE OF OBSTETRICIANS AND GYNAECOLOGISTS, SINGAPORE 2006 CONSENSUS STATEMENT ON THE MANAGEMENT AND EVALUATION OF MENORRHAGIA (INCLUDING MANAGEMENT OF FIBROIDS) Introduction Menorrhagia is defined as
More informationMENOPAUSE. I have no disclosures 10/11/18 OBJECTIVES WHAT S NEW? WHAT S SAFE?
MENOPAUSE WHAT S NEW? WHAT S SAFE? I have no disclosures Sara Whetstone, MD, MHS OBJECTIVES To describe risks of HT by age and menopause onset To recommend specific HT regimen for women who undergo early
More informationOVERVIEW OF MENOPAUSE
OVERVIEW OF MENOPAUSE Nicole Budrys, MD, MPH Reproductive Endocrinology Michigan Center for Fertility and Women s Health Presented at SEMCME March 13,2019 Objectives Define menopause Etiology of menopause
More informationThe effect of tamoxifen therapy on the endometrium and ovarian cyst formation in patients with breast cancer
Original Article Obstet Gynecol Sci 2018;61(5):615-620 https://doi.org/10.5468/ogs.2018.61.5.615 pissn 2287-8572 eissn 2287-8580 The effect of tamoxifen therapy on the endometrium and ovarian cyst formation
More informationHormone therapy for menopausal vasomotor symptoms
Hormone therapy for menopausal vasomotor symptoms Given our available (better) options for treating hot flashes, can we reduce our use of medroxyprogesterone acetate? OBG Manag. 2014;26(7):10,13 15. Robert
More informationIntrauterine delivery of progestogen in the peri- and postmenopausal women. Outline of the presentation. Levonorgestrel releasing IUS - Mirena
QuickTime ja Valokuva - JPEG pakkauksen purkuohjelma tarvitaan elokuvan katselemiseen. Intrauterine delivery of progestogen in the peri- and postmenopausal women ESHRE Campus meeting 6.-7.10.2008 Oskari
More informationCLEAR COVERAGE HYSTERECTOMY CHECKLISTS
CLEAR COVERAGE HYSTERECTOMY CHECKLISTS Click on the link below to access the checklist sheet. Abnormal Uterine Bleeding Adenomyosis Chronic Abdominal or Pelvic Pain Endometriosis Fibroids General Guidelines
More informationDr. Nancy Van Eyk Associate Professor, Dalhousie University Chief of Gynaecology, IWK Health Centre
Dr. Nancy Van Eyk Associate Professor, Dalhousie University Chief of Gynaecology, IWK Health Centre AUB Outline Terminology Classification/Etiology Assessment Treatment Referral to Gynaecology U c pt 4
More informationBLEEDING PATTERNS AND CONTRACEPTIVE DISCONTINUATION FG MHLANGA MTN ANNUAL MEETING 20 MARCH 2018
BLEEDING PATTERNS AND CONTRACEPTIVE DISCONTINUATION FG MHLANGA MTN ANNUAL MEETING 20 MARCH 2018 Introduction Bleeding with contraception may lead to discontinuation and possible unintended pregnancy What
More informationCitation for published version (APA): Timmermans, A. (2009). Postmenopausal bleeding : studies on the diagnostic work-up
UvA-DARE (Digital Academic Repository) Postmenopausal bleeding : studies on the diagnostic work-up Timmermans, A. Link to publication Citation for published version (APA): Timmermans, A. (2009). Postmenopausal
More informationIs Outpatient Hysteroscopy the New Gold Standard?
Is Outpatient Hysteroscopy the New Gold Standard? McIlwaine K, Readman E, Ma T, Manwaring J, Ellett L, Hicks L, Porter J, Cameron M, Maher P. Mercy Hospital for Women, Melbourne, Australia Background Abnormal
More informationFirst-generation endometrial ablation revisited: retrospective outcome study a series of 218 patients with premenopausal dysfunctional bleeding
Gynecol Surg (2015) 12:291 297 DOI 10.1007/s10397-015-0902-8 ORIGINAL ARTICLE First-generation endometrial ablation revisited: retrospective outcome study a series of 218 patients with premenopausal dysfunctional
More informationComparative Study of Transvaginal Sonography and Hysteroscopy for the Detection /jp-journals
JSAFOG Comparative Study of Transvaginal Sonography and Hysteroscopy for the Detection 10.5005/jp-journals-10006-1580 of Endometrial Lesions in Women ORIGINAL ARTICLE Comparative Study of Transvaginal
More informationAbnormal Uterine Bleeding
Abnormal Uterine Bleeding Randy A. Fink, MD, FACOG Obstetrics & Gynecology A simplified approach for primary care Disclosures I have no relevant disclosures pertaining to this program. Learning Objectives
More informationChawla Indu Tripathi Suchita Vohra Poonam Singh Pushpa
DOI 10.1007/s13224-013-0501-4 ORIGINAL ARTICLE To Evaluate the Accuracy of Saline Infusion Sonohysterography (SIS) for Evaluation of Uterine Cavity Abnormalities in Patients with Abnormal Uterine Bleeding
More informationDiagnostic accuracy of sonohysterography compared to endometrial biopsy in pre-menopausal women with abnormal uterine bleeding
Original Article Medical Journal of the Islamic Republic of Iran (MJIRI) Iran University of Medical Sciences Diagnostic accuracy of sonohysterography compared to endometrial biopsy in pre-menopausal women
More informationArticle begins on next page
Association of cervical microglandular hyperplasia with exogenous progestin exposure Rutgers University has made this article freely available. Please share how this access benefits you. Your story matters.
More informationAbnormal Uterine Bleeding Case Studies
Case Study 1 Abnormal Uterine Bleeding Case Studies Abigail, a 24 year old female, presents to your office complaining that her menstrual cycles have become a problem. They are now lasting 6 7 days instead
More informationDisclosures. REPLENISH Trial: Objective and Design. Background Use of compounded bioidentical hormone therapy (CBHT) has become highly prevalent
17β Estradiol/Progesterone in a Single Oral Softgel Capsule (TX 001HR) Significantly Reduced Moderate to Severe Vasomotor Symptoms without Endometrial Hyperplasia Disclosures Research support: Actavis,
More informationMenorrhagia Update. Simon Edmonds Middlemore Hospital Ascot Central Women s Clinic Auckland
Menorrhagia Update Simon Edmonds Middlemore Hospital Ascot Central Women s Clinic Auckland What is it? Subjective Excessive blood loss at time of menstruation flooding heavy clots Objective > 80mls volume
More informationMEDICAL POLICY SUBJECT: ENDOMETRIAL ABLATION
MEDICAL POLICY PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationHKCOG Guidelines. Guidelines for the Administration of Hormone Replacement Therapy. Number 2 revised January 2003
HKCOG Guidelines Guidelines for the Administration of Hormone Replacement Therapy Number 2 revised January 2003 published by The Hong Kong College of Obstetricians and Gynaecologists A Foundation College
More informationPage # 1. Endometrium. Cellular Components. Anatomical Regions. Management of SIL Thomas C. Wright, Jr. Most common diseases:
Endometrium Pathology of the Endometrium Thomas C. Wright Columbia University, New York, NY Most common diseases: Abnormal uterine bleeding Inflammatory conditions Benign neoplasms Endometrial cancer Anatomical
More informationColumbia University Medical Center, New York, NY 2. Clinical Research Center, Eastern Virginia Medical School, Norfolk, VA 3
17β-Estradiol/Progesterone in a Single Oral Softgel Capsule (TX-001HR) Significantly Reduced Moderate-to-Severe Vasomotor Symptoms without Endometrial Hyperplasia Rogerio A Lobo, MD 1 ; David F Archer,
More informationIMPORTANT REMINDER DESCRIPTION
Medical Policy Manual Surgery, Policy No. 01 Endometrial Ablation Next Review: February 2019 Last Review: September 2018 Effective: October 1, 2018 IMPORTANT REMINDER Medical Policies are developed to
More information4. Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms
550 4. Other Data Relevant to an Evaluation of Carcinogenicity and its Mechanisms 4.1 Absorption, distribution, metabolism and excretion 4.1.1 Humans The pharmacokinetics of the newer progestogens, desogestrel,
More informationDiagnostic Features and Therapeutic Consequences of Hysteroscopy in Women with Abnormal Uterine Bleeding and Abortion
American Journal of Applied Sciences 9 (1): 13-17, 2012 ISSN 1546-9239 2012 Science Publications Diagnostic Features and Therapeutic Consequences of Hysteroscopy in Women with Abnormal Uterine Bleeding
More informationPostmenopausal Asymptomatic. Endometrial Thickening: Patient. Characteristics and Pathology
Research Article imedpub Journals www.imedpub.com Womens Health and Reproductive Medicine Abstract Postmenopausal Asymptomatic Endometrial Thickening: Patient Characteristics and Pathology Background:
More informationUterine-Sparing Treatment Options for Symptomatic Uterine Fibroids
Uterine-Sparing Treatment Options for Symptomatic Uterine Fibroids Developed in collaboration Learning Objective Upon completion, participants should be able to: Review uterine-sparing fibroid therapies
More informationResearch. Breast cancer represents a major
Research GENERAL GYNECOLOGY Gynecologic conditions in participants in the NSABP breast cancer prevention study of tamoxifen and raloxifene (STAR) Carolyn D. Runowicz, MD; Joseph P. Costantino, DrPH; D.
More information